Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
复制标题
自体细胞因子诱导杀伤 (CIK) 细胞增强晚期非小细胞肺癌患者对 PD-1 阻断抗体的临床反应：一项初步研究
DOI：
10.1111/1759-7714.13731
复制
发表时间：
2021-01
期刊：
影响因子：
2.9
通讯作者：
Ren X
中科院分区：
文献类型：
--
作者：
Han Y;Mu D;Liu T;Zhang H;Zhang J;Li S;Wang R;Du W;Hui Z;Zhang X;Ren X
已显示抗体的程序死亡1（PD -1）已被证明可以改善无进度生存率（PFS）和非小细胞肺癌（NSCLC）的子集中的总体存活率（NSCLC），但是，这些药物的客观反应率仍然很低。细胞因子诱导的杀伤（CIK）细胞输注结合NSCLC患者的PD-1阻断抗体。
在这项初步研究中，我们研究了PD -1 blocade抗体Pembrolizumab或Nivolumab的安全性和免疫功能有效性，并结合了或没有自体内的CIK细胞输注，在18例患者中与这些细胞相比，在18例患者中均与某些细胞相比，在18例患者中均具有p.该组合方案。
与预处理水平相比，两者中均未发生与治疗相关的死亡，CD3+CD56+CD16+T细胞随着组合疗法而显着增加，而髓样抑制细胞则与PD -1的抑制作用显着增加，而PD -1则仅与组合疗法相结合。没有变化。
这项临床研究的目的是报告临床效率和缺乏加重的自身免疫不良事件，并在晚期NSCLC患者中结合了PD -1阻断和CIK细胞输注，进一步支持对未来临床试验中这种组合的评估。
我们对PD-1封闭抗体（Pembrolizumab或Nivolumab）以及自体CIK细胞进行了回顾性研究，以评估该治疗的安全性，有效性和对该治疗的免疫学功能的影响，总共有18例患者，我们在疾病控制率（DCR）中受到了pD-1的较高范围。仅抗体，这项临床研究就可以为未来的进一步临床试验提供数据支持。
Programmed death‐1 (PD‐1) blocking antibodies have been shown to improve progression‐free survival (PFS) and overall survival in a subset of patients with non–small cell lung cancer (NSCLC). However, the objective response rate with these agents remains low, and the vast majority of NSCLC patients require alternative combination treatment regimens to prolong their survival. The purpose of this study was to evaluate the clinical efficacy of autologous cytokine‐induced killer (CIK) cell infusions combined with PD‐1 blocking antibodies in patients with NSCLC. In this preliminary study, we investigated the safety and immune function effectiveness of PD‐1 blockade antibodies pembrolizumab or nivolumab administered in combination with or without autologous CIK cell infusions in 18 patients with advanced NSCLC. The peripheral blood mononuclear cells were isolated from these patients and the expression level of some cell surface molecules like PD‐1 were detected using flow cytometry to reflect the effectiveness of this combination regimen. No treatment‐related deaths occurred in either cohort. In comparison with the pretreatment level, CD3+CD56+CD16+ T cells were significantly increased with the combination therapy, while myeloid‐derived suppressor cells were significantly increased with PD‐1 blocking antibody therapy alone but not with combination therapy. Although the serum interleukin‐4 level was downregulated following treatment with the combination regimen, interferon‐γ levels were unchanged. The purpose of this clinical study was to report the clinical efficacy and lack of exacerbated autoimmune adverse events with a combination of PD‐1 blockade and CIK cell infusions in patients with advanced NSCLC, further supporting assessments of this combination in future clinical trials. We conducted a retrospective study of PD‐1 blocking antibodies (pembrolizumab or nivolumab) plus autologous CIK cells to assess the safety, effectiveness, and influence on immune function of this treatment in a total of 18 patients with advanced NSCLC. We found that disease control rate (DCR) was significantly higher in patients who received a combination of PD‐1 blockade + CIK cell infusions than in those who received a PD‐1 blocking antibody alone. This clinical study provides data support for further clinical trials in the future.
登录
查看更多内容
发现NKT细胞和NKT细胞靶向的抗肿瘤免疫疗法的发展。
DOI：
10.2183/pjab.91.292
发表时间：
2015
期刊：
Proceedings of the Japan Academy. Series B, Physical and biological sciences
影响因子：
--
作者：
Taniguchi M;Harada M;Dashtsoodol N;Kojo S
通讯作者：
Kojo S
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
5.8
作者：
Li, Runmei;Wang, Changli;Li, Hui
通讯作者：
Li, Hui
影响因子：
17.1
作者：
Highfill SL;Cui Y;Giles AJ;Smith JP;Zhang H;Morse E;Kaplan RN;Mackall CL
通讯作者：
Mackall CL
影响因子：
7.3
作者：
Hui Z;Zhang X;Ren B;Li R;Ren X
通讯作者：
Ren X